Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007
Telavancin vs. linezolid in an animal model of severe MRSA pneumonia Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004
Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004